MVA-BN (modified vaccinia Ankara-Bavarian Nordic) vaccination is safe and well tolerated among at-risk adults, with low rates of severe adverse reactions.
Vaccine effectiveness (VE) for one dose is moderate (58–76%) but improves with two doses (82%). Effectiveness is notably reduced in people living with HIV.
Breakthrough mpox infections after vaccination are milder compared to those in unvaccinated individuals.
Host baseline immunological states may influence vaccine response and need to be considered in vaccination strategies, especially with constrained vaccine supply.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.